Johnson & Johnson (NYSE:JNJ) Stock Holdings Trimmed by Mondrian Investment Partners LTD

Share on StockTwits

Mondrian Investment Partners LTD trimmed its position in Johnson & Johnson (NYSE:JNJ) by 23.4% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 602,196 shares of the company’s stock after selling 183,658 shares during the period. Johnson & Johnson accounts for 2.5% of Mondrian Investment Partners LTD’s portfolio, making the stock its 10th biggest position. Mondrian Investment Partners LTD’s holdings in Johnson & Johnson were worth $77,912,000 at the end of the most recent quarter.

A number of other hedge funds have also recently modified their holdings of the stock. Virtus ETF Advisers LLC bought a new position in Johnson & Johnson in the second quarter valued at about $25,000. Krane Funds Advisors LLC bought a new position in Johnson & Johnson in the second quarter valued at about $26,000. Financial Advantage Inc. bought a new position in Johnson & Johnson in the third quarter valued at about $28,000. Crewe Advisors LLC lifted its holdings in Johnson & Johnson by 725.9% in the second quarter. Crewe Advisors LLC now owns 223 shares of the company’s stock valued at $31,000 after acquiring an additional 196 shares during the period. Finally, Eii Capital Management Inc. bought a new position in Johnson & Johnson in the third quarter valued at about $39,000. 72.22% of the stock is currently owned by institutional investors.

JNJ traded down $0.02 during midday trading on Wednesday, reaching $131.33. The company had a trading volume of 2,034,376 shares, compared to its average volume of 7,202,121. The company has a quick ratio of 1.00, a current ratio of 1.26 and a debt-to-equity ratio of 0.46. The business has a 50-day moving average of $130.88 and a two-hundred day moving average of $133.96. The company has a market cap of $350.04 billion, a P/E ratio of 16.06, a P/E/G ratio of 2.25 and a beta of 0.69. Johnson & Johnson has a 1 year low of $121.00 and a 1 year high of $148.99.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Tuesday, October 15th. The company reported $2.12 EPS for the quarter, topping analysts’ consensus estimates of $2.00 by $0.12. The business had revenue of $20.73 billion during the quarter, compared to analysts’ expectations of $20.14 billion. Johnson & Johnson had a return on equity of 39.81% and a net margin of 21.09%. The business’s quarterly revenue was up 1.9% on a year-over-year basis. During the same quarter in the prior year, the business posted $2.05 earnings per share. On average, equities research analysts predict that Johnson & Johnson will post 8.65 EPS for the current year.

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 10th. Shareholders of record on Tuesday, November 26th will be given a $0.95 dividend. This represents a $3.80 dividend on an annualized basis and a yield of 2.89%. The ex-dividend date is Monday, November 25th. Johnson & Johnson’s payout ratio is 46.45%.

A number of research analysts have weighed in on the company. Raymond James lowered their target price on Johnson & Johnson from $146.00 to $145.00 and set an “outperform” rating on the stock in a report on Monday, October 14th. Bank of America reissued a “hold” rating and issued a $150.00 target price on shares of Johnson & Johnson in a report on Tuesday, July 16th. Sanford C. Bernstein raised Johnson & Johnson from a “market perform” rating to an “outperform” rating and set a $155.00 target price on the stock in a report on Friday, October 11th. Morgan Stanley reissued an “equal weight” rating and issued a $145.00 target price on shares of Johnson & Johnson in a report on Tuesday, August 27th. Finally, Wells Fargo & Co lowered their target price on Johnson & Johnson from $157.00 to $155.00 and set an “outperform” rating on the stock in a report on Wednesday, October 16th. Six equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. The company has an average rating of “Buy” and a consensus price target of $151.64.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

See Also: After-Hours Trading

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.